; (C) $10,000,000 for fiscal year 2019, and such sums as may be necessary for each of fiscal years 2020 through 2023, for the activities described in section 417H(b)(1)(D) of the Public Health Service Act; and (D) $15,000,000 for fiscal year 2019, and such sums as may be necessary for each of fiscal years 2020 through 2023, for the activities described in section 417H(b)(3) of the Public Health Service Act. 702. Expanding prostate cancer research, outreach, screening, testing, access, and treatment effectiveness (a) Short Title This section may be cited as the Prostate Research, Outreach, Screening, Testing, Access, and Treatment Effectiveness Act of 2018 or the PROSTATE Act . (b) Findings Congress makes the following findings: (1) Prostate cancer is the second leading cause of cancer death among men. (2) In 2018, an estimated 164,690 men will be diagnosed with prostate cancer and more than 29,000 will die from this disease. (3) Roughly 2,000,000 to 3,000,000 people in the United States are living with a diagnosis of prostate cancer and its consequences. (4) While prostate cancer generally affects older individuals, younger men are also at risk for the disease, and when prostate cancer appears in early middle age, it frequently takes on a more aggressive form. (5) There are significant racial and ethnic disparities that demand attention